114 related articles for article (PubMed ID: 9289779)
1. [The mechanism of action of hypolipidemic drugs].
Scheen AJ
Rev Med Liege; 1997 Jun; 52(6):445-6. PubMed ID: 9289779
[No Abstract] [Full Text] [Related]
2. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
3. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
Ness GC; Zhao Z; Lopez D
Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
[TBL] [Abstract][Full Text] [Related]
6. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
Hughes AD
J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802
[TBL] [Abstract][Full Text] [Related]
7. [The role of HDL in the prevention of cardiovascular events].
Paragh G; Harangi M
Orv Hetil; 2001 Jan; 142(3):121-6. PubMed ID: 11217160
[TBL] [Abstract][Full Text] [Related]
8. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
al Rayyes O; Wallmark A; Florén CH
Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609
[TBL] [Abstract][Full Text] [Related]
9. [Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant].
Stalenhoef AF; Stehouwer CD
Ned Tijdschr Geneeskd; 2000 Feb; 144(7):308-10. PubMed ID: 10707739
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
11. [Drug of the month. Fluvastatin (Lescol)].
Scheen AJ
Rev Med Liege; 1997 Jun; 52(6):442-4. PubMed ID: 9289778
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
13. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Dansette PM; Jaoen M; Pons C
Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
[TBL] [Abstract][Full Text] [Related]
14. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637
[TBL] [Abstract][Full Text] [Related]
15. Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
Charmoillaux M; Goudonnet H; Mercenne F; Mounié J; Truchot RC
Cell Mol Biol; 1991; 37(8):765-71. PubMed ID: 1807786
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients.
Pazzucconi F; Franceschini G; Gianfranceschi G; Campagnoli G; Sirtori CR
Pharmacol Res; 1996; 34(3-4):131-3. PubMed ID: 9051704
[TBL] [Abstract][Full Text] [Related]
17. Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors.
Sehayek E; Butbul E; Avner R; Levkovitz H; Eisenberg S
Eur J Clin Invest; 1994 Mar; 24(3):173-8. PubMed ID: 8033951
[TBL] [Abstract][Full Text] [Related]
18. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Branchi A; Rovellini A; Fiorenza AM; Sommariva D
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
[TBL] [Abstract][Full Text] [Related]
19. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
[TBL] [Abstract][Full Text] [Related]
20. Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia.
Koter M; Franiak I; Broncel M; Chojnowska-Jezierska J
Can J Physiol Pharmacol; 2003 May; 81(5):485-92. PubMed ID: 12774855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
